aTyr Plans to Submit New Drug Application for efzofitimod Next Month
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ATYR?
"2026 is off to a productive start, as we now have a clear path forward for efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease, following our recent Type C meeting with the U.S. Food and Drug Administration," said Sanjay S. Shukla, president and CEO of aTyr. "Based on feedback from the FDA, we plan to file an investigational new drug application next month for a new Phase 3 study in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing forced vital capacity as the primary endpoint of the study and the King's Sarcoidosis Questionnaire-Lung score as a key secondary endpoint. We look forward to the continued advancement of efzofitimod in this form of ILD where there remains a high unmet medical need."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATYR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATYR
Wall Street analysts forecast ATYR stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 0.560
Low
1.00
Averages
1.00
High
1.00
Current: 0.560
Low
1.00
Averages
1.00
High
1.00
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
aTyr Pharma Q1 Earnings Beat Expectations
- Earnings Highlights: aTyr Pharma reported a Q1 GAAP EPS of -$0.11, beating expectations by $0.04, indicating improvements in cost control and operational efficiency, although the company remains in a loss position.
- Cash Position: As of March 31, 2026, aTyr Pharma's total cash, cash equivalents, restricted cash, and available-for-sale investments amounted to $68.3 million, providing substantial funding for future R&D and operations, thereby enhancing financial stability.
- FDA Feedback Discussion: aTyr Pharma engaged in detailed discussions with the FDA regarding Efzofitimod's Phase III trial results for pulmonary sarcoidosis, demonstrating the company's proactive approach to advancing its drug towards market approval, which could pave the way for future market access.
- Strategic Development Focus: The company emphasized its commitment to developing treatments for pulmonary sarcoidosis, planning to accelerate subsequent clinical trials in light of FDA feedback, thereby enhancing its competitiveness in the biopharmaceutical sector.
See More
aTyr Pharma Advances efzofitimod Development in Pulmonary Sarcoidosis
- Positive FDA Feedback: aTyr Pharma received encouraging feedback from the FDA regarding the development of efzofitimod for pulmonary sarcoidosis, planning to submit an IND application in June 2026, marking a strategic advancement in addressing this significant disease.
- Clinical Trial Design: The new Phase 3 clinical trial will utilize forced vital capacity (FVC) as the primary endpoint, aiming to enroll approximately 372 patients over a 54-week period to evaluate the efficacy and safety of efzofitimod, further validating its clinical value.
- Dosing Strategy Adjustment: The company plans to increase the dosing frequency of efzofitimod from once every four weeks to once every three weeks, aiming to enhance drug exposure and efficacy while maintaining safety, demonstrating a strong commitment to patient safety.
- Focused Patient Population: This study will concentrate on patients with chronic, symptomatic pulmonary sarcoidosis, particularly those with FVC percent predicted ≤ 80%, aiming to improve clinical outcomes through targeted treatment and meet the urgent market demand for new therapies.
See More
aTyr Pharma Q4 Earnings Beat Expectations
- Earnings Report: aTyr Pharma reported a Q4 GAAP EPS of -$0.14, beating market expectations by $0.02, indicating improvements in financial management that may bolster investor confidence.
- Cash Reserves: As of 2025, the company holds $80.9 million in cash, cash equivalents, restricted cash, and investments, ensuring sufficient funding for future R&D and operations, supporting its long-term strategic goals.
- FDA Meeting Plans: aTyr Pharma is set to meet with the FDA in April to discuss its lead asset, a move that could pave the way for future product approvals and enhance market recognition of its R&D capabilities.
- Market Attention: Seeking Alpha's Quant Rating on aTyr Pharma reflects market interest in its financial performance, potentially attracting more investors to the company's growth prospects.
See More
aTYR Pharma Reports Reduced Q4 Loss
- Financial Performance Improvement: aTYR Pharma reported a fourth-quarter loss of $13.96 million, or $0.14 per share, which is an improvement from last year's loss of $14.97 million, or $0.18 per share, indicating a positive trend in financial health.
- Year-over-Year Comparison: Although still in the red, the narrowing of losses suggests that the company may have made progress in cost control and operational efficiency, which could enhance investor confidence in future profitability.
- Market Reaction Expectations: With the reduction in losses, the market may adopt a more optimistic outlook on aTYR Pharma's future performance, particularly in the competitive biopharmaceutical sector, where financial improvements could attract more investor interest.
- Strategic Adjustment Necessity: Despite the reduced losses, the company must continue to optimize its business strategy to achieve profitability, especially in terms of investments in R&D and marketing to ensure long-term sustainable growth.
See More
aTyr Pharma Sets Timeline for FDA Meeting
- FDA Meeting Scheduled: aTyr Pharma has announced a Type C meeting with the FDA in mid-April 2026 to discuss the results of its EFZO-FIT study for the lung disease candidate efzofitimod, marking a significant step in advancing the drug's development.
- Impact of Clinical Trial Failure: In September, aTyr's efzofitimod failed in a Phase 3 trial for pulmonary sarcoidosis, leading to a drop in the company's stock price and raising concerns about its research and development capabilities in the market.
- Market Reaction: Following the announcement of the FDA meeting timeline, aTyr's shares fell approximately 8% on Tuesday, reflecting investor uncertainty about the company's future, particularly after the clinical trial failure.
- Patient Impact: Pulmonary sarcoidosis affects around 200,000 Americans, and if aTyr can successfully advance efzofitimod, it would provide a new treatment option for this patient population, carrying significant social and economic implications.
See More
aTyr Pharma Schedules FDA Meeting for efzofitimod Review
- FDA Meeting Scheduled: aTyr Pharma has received FDA approval for a meeting in mid-April 2026 to discuss the results of its Phase 3 EFZO-FIT™ study for efzofitimod, which is expected to provide guidance for future development pathways.
- Clinical Trial Results: Although the EFZO-FIT™ study did not meet its primary endpoint, clinical benefits were observed for efzofitimod across multiple efficacy parameters in 268 patients, particularly with improvements in the KSQ-Lung score and Fatigue Assessment Scale, achieving p=0.0479 and p=0.0226, respectively.
- Safety and Tolerability: Efzofitimod demonstrated good maintenance of lung function and a safety profile consistent with prior trials, indicating its potential application in treating pulmonary sarcoidosis.
- Market Demand and Growth Potential: With increasing demand for safe and effective treatments for lung diseases, efzofitimod, as a novel biologic immunomodulator, may open new market opportunities in the interstitial lung disease space, addressing urgent patient needs.
See More
aTyr Pharma Q1 Earnings Beat Expectations
- Earnings Highlights: aTyr Pharma reported a Q1 GAAP EPS of -$0.11, beating expectations by $0.04, indicating improvements in cost control and operational efficiency, although the company remains in a loss position.
- Cash Position: As of March 31, 2026, aTyr Pharma's total cash, cash equivalents, restricted cash, and available-for-sale investments amounted to $68.3 million, providing substantial funding for future R&D and operations, thereby enhancing financial stability.
- FDA Feedback Discussion: aTyr Pharma engaged in detailed discussions with the FDA regarding Efzofitimod's Phase III trial results for pulmonary sarcoidosis, demonstrating the company's proactive approach to advancing its drug towards market approval, which could pave the way for future market access.
- Strategic Development Focus: The company emphasized its commitment to developing treatments for pulmonary sarcoidosis, planning to accelerate subsequent clinical trials in light of FDA feedback, thereby enhancing its competitiveness in the biopharmaceutical sector.
See More
aTyr Pharma Advances efzofitimod Development in Pulmonary Sarcoidosis
- Positive FDA Feedback: aTyr Pharma received encouraging feedback from the FDA regarding the development of efzofitimod for pulmonary sarcoidosis, planning to submit an IND application in June 2026, marking a strategic advancement in addressing this significant disease.
- Clinical Trial Design: The new Phase 3 clinical trial will utilize forced vital capacity (FVC) as the primary endpoint, aiming to enroll approximately 372 patients over a 54-week period to evaluate the efficacy and safety of efzofitimod, further validating its clinical value.
- Dosing Strategy Adjustment: The company plans to increase the dosing frequency of efzofitimod from once every four weeks to once every three weeks, aiming to enhance drug exposure and efficacy while maintaining safety, demonstrating a strong commitment to patient safety.
- Focused Patient Population: This study will concentrate on patients with chronic, symptomatic pulmonary sarcoidosis, particularly those with FVC percent predicted ≤ 80%, aiming to improve clinical outcomes through targeted treatment and meet the urgent market demand for new therapies.
See More
aTyr Pharma Q4 Earnings Beat Expectations
- Earnings Report: aTyr Pharma reported a Q4 GAAP EPS of -$0.14, beating market expectations by $0.02, indicating improvements in financial management that may bolster investor confidence.
- Cash Reserves: As of 2025, the company holds $80.9 million in cash, cash equivalents, restricted cash, and investments, ensuring sufficient funding for future R&D and operations, supporting its long-term strategic goals.
- FDA Meeting Plans: aTyr Pharma is set to meet with the FDA in April to discuss its lead asset, a move that could pave the way for future product approvals and enhance market recognition of its R&D capabilities.
- Market Attention: Seeking Alpha's Quant Rating on aTyr Pharma reflects market interest in its financial performance, potentially attracting more investors to the company's growth prospects.
See More
aTYR Pharma Reports Reduced Q4 Loss
- Financial Performance Improvement: aTYR Pharma reported a fourth-quarter loss of $13.96 million, or $0.14 per share, which is an improvement from last year's loss of $14.97 million, or $0.18 per share, indicating a positive trend in financial health.
- Year-over-Year Comparison: Although still in the red, the narrowing of losses suggests that the company may have made progress in cost control and operational efficiency, which could enhance investor confidence in future profitability.
- Market Reaction Expectations: With the reduction in losses, the market may adopt a more optimistic outlook on aTYR Pharma's future performance, particularly in the competitive biopharmaceutical sector, where financial improvements could attract more investor interest.
- Strategic Adjustment Necessity: Despite the reduced losses, the company must continue to optimize its business strategy to achieve profitability, especially in terms of investments in R&D and marketing to ensure long-term sustainable growth.
See More
aTyr Pharma Sets Timeline for FDA Meeting
- FDA Meeting Scheduled: aTyr Pharma has announced a Type C meeting with the FDA in mid-April 2026 to discuss the results of its EFZO-FIT study for the lung disease candidate efzofitimod, marking a significant step in advancing the drug's development.
- Impact of Clinical Trial Failure: In September, aTyr's efzofitimod failed in a Phase 3 trial for pulmonary sarcoidosis, leading to a drop in the company's stock price and raising concerns about its research and development capabilities in the market.
- Market Reaction: Following the announcement of the FDA meeting timeline, aTyr's shares fell approximately 8% on Tuesday, reflecting investor uncertainty about the company's future, particularly after the clinical trial failure.
- Patient Impact: Pulmonary sarcoidosis affects around 200,000 Americans, and if aTyr can successfully advance efzofitimod, it would provide a new treatment option for this patient population, carrying significant social and economic implications.
See More
aTyr Pharma Schedules FDA Meeting for efzofitimod Review
- FDA Meeting Scheduled: aTyr Pharma has received FDA approval for a meeting in mid-April 2026 to discuss the results of its Phase 3 EFZO-FIT™ study for efzofitimod, which is expected to provide guidance for future development pathways.
- Clinical Trial Results: Although the EFZO-FIT™ study did not meet its primary endpoint, clinical benefits were observed for efzofitimod across multiple efficacy parameters in 268 patients, particularly with improvements in the KSQ-Lung score and Fatigue Assessment Scale, achieving p=0.0479 and p=0.0226, respectively.
- Safety and Tolerability: Efzofitimod demonstrated good maintenance of lung function and a safety profile consistent with prior trials, indicating its potential application in treating pulmonary sarcoidosis.
- Market Demand and Growth Potential: With increasing demand for safe and effective treatments for lung diseases, efzofitimod, as a novel biologic immunomodulator, may open new market opportunities in the interstitial lung disease space, addressing urgent patient needs.
See More
